Apalutamide for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Feb 2024: Trial registered, NCT06274047
  2. 10 Sep 2024: Trial started, NCT06274047

The trials

NCT06274047: PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

State
Under way
Phase
Phase 3
People
120 planned
Started
10 Sep 2024
Primary completion
30 Jun 2027
Arms
Arm 2
Results
None posted
  1. 23 Feb 2024: Trial registered
  2. 10 Sep 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Erleada.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.